

T-CELL CLONALITY ASSESSMENT BY FLOW CYTOMETRY USING ANTI-TCR-Cb-1: INITIAL EXPERIENCE OF A SINGLE CENTER

Vladimirova Rositsa, Muhtarova Maria, Jagurinoski Milan, Vasilev Georgi, Balatzenko Gueorgui, Guenova Margarita

Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria.

Background: Clonality assessment in the diagnosis of reactive and neoplastic T-cell proliferations could be challenging in routine practice requiring expensive and time consuming molecular testing. The recent discovery of a monoclonal antibody specific for human TCR β C1 placed in our hands a new opportunity to detect clonality of immunophenotypically distinct T-cell populations by flow cytometry.

Aim: To develop a flow cytometric approach to establish clonality in mature T-cell lymphocytes by incorporating an anti-TCR β C1(JOVI-1) antibody specific for one of the two mutually exclusive β -chains.

Methods: Since March 2023 8 samples of peripheral blood and 3 of bone marrow from 11 patients (4 men; 7 women; mean age 56,5 \pm 18,43) with absolute lymphocytosis (71,19 \pm 184.2 \times 10⁹/L) were studied by antibodies against T-cell (CD3, CD4, CD8, CD2, CD5, CD7, CD26), B-cell (CD19, CD20), and NK-cell (CD56) markers as well as antibodies to characterise T-cell receptor (TCR α / β , TCR γ / δ , TCR β C1(JOVI-1) using 12-color stain-lysewash flow cytometry (FACSLytic, BD). TCR β C1 expression of <15% or >85% was considered monotypic.

Results: T-cell populations defined as clonal based on \geq 85% positive or negative TCR β C1(JOVI-1) immunolabeling were identified in 6 patients: CD3(+)CD4(+) in two, CD3(+)CD8(+) in three and CD3(+)CD4(+)CD8(+) in one. The remaining T-cell subpopulations in these cases showed a polyclonal TCR β C1(+):TCR β C1(-) distribution - median TCR β C1-positivity was 41.7% (range 21.1–55.7%) . In 4 patients, the analysis showed negative clonality with polyclonal TCR β C1(+):TCR β C1(-) distribution maintained in all subpopulations (median TCR β C1-positivity 41.3.0%; range 30–49.9%). Monotypic cases showed significantly higher absolute lymphocyte counts (ALC) compared to those lacking clonality (mean ALC 137.4 \times 10⁹/L; range 5.6-527 \times 10⁹/L vs 4.5 \times 10⁹/L; range 3.2-6.2 \times 10⁹/L, respectively) as well as aberrant morphology and/or phenotypes in 4/6 patients. In one case, the presence of oligoclonality was detected: there were 1.7 \times 10⁹/L CD3(+)CD4(+)CD7(-)CD26(-) T-cells with TCR β C1(JOVI-1) negativity in 90% and 0.3 \times 10⁹/L CD3(+)CD4(+)CD8(+) T cells, 95% of which were TCR β C1(JOVI-1)(-). However, no other clinical or laboratory abnormalities were present and the case raised the question of a T-CUS (T-cell clones of uncertain significance).

Conclusion: Concordant with published data, the incorporation of TCR β C1(JOVI-1) antibody in flow cytometric immunophenotyping panels allowed us rapid and reproducible determination of clonality in mature T-cell lymphoproliferations and facilitated the differentiation of reactive from neoplastic processes in the diagnostic process.

References

Shi M, Jevremovic D, Otteson GE, et al. Single antibody detection of T-cell receptor ab clonality by flow cytometry rapidly identifies mature T-cell neoplasms and monotypic small CD8-positive subsets of uncertain significance. *Cytometry B Clin Cytom* 2020; 98: 9